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Abstract: Thrombotic material retrieved from acute ischemic stroke (AIS) patients represents a
valuable source of biological information. In this study, we have developed a clinical proteomics
workflow to characterize the protein cargo of thrombi derived from AIS patients. To analyze
the thrombus proteome in a large-scale format, we developed a workflow that combines the
isolation of thrombus by endovascular thrombectomy and peptide chromatographic fractionation
coupled to mass-spectrometry. Using this workflow, we have characterized a specific proteomic
expression profile derived from four AIS patients included in this study. Around 1600 protein
species were unambiguously identified in the analyzed material. Functional bioinformatics analyses
were performed, emphasizing a clustering of proteins with immunological functions as well as
cardiopathy-related proteins with blood-cell dependent functions and peripheral vascular processes.
In addition, we established a reference proteomic fingerprint of 341 proteins commonly detected in
all patients. Protein interactome network of this subproteome revealed protein clusters involved
in the interaction of fibronectin with 14-3-3 proteins, TGFβ signaling, and TCP complex network.
Taken together, our data contributes to the repertoire of the human thrombus proteome, serving as a
reference library to increase our knowledge about the molecular basis of thrombus derived from AIS
patients, paving the way toward the establishment of a quantitative approach necessary to detect and
characterize potential novel biomarkers in the stroke field.
Int. J. Mol. Sci. 2018, 19, 498; doi:10.3390/ijms19020498 www.mdpi.com/journal/ijms
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1. Introduction
Stroke represents one of the top causes of mortality and adult disability worldwide [1].
Currently, secondary preventive therapy to avoid stroke recurrence is based on the etiological
classification of acute ischemic stroke (AIS) following the Trial of Org 10172 in Acute Stroke Treatment
(TOAST) classification [2]. Regardless of the significant diagnostic effort in the clinical setting, up to
30% of stroke patients are discharged with an undetermined or unknown etiology diagnosis [3].
Lately, blood-based biomarkers have arisen as promising tools to help in the diagnosis of stroke
etiology. However, these biomarkers still lack sufficient sensitivity and specificity to be implemented
in the clinical setting [4]. Hopefully, the integration of new “omics” techniques will provide a
comprehensive approach to study the thrombotic processes. That will be most helpful to identify novel
blood biomarkers with better predictive values in the stroke field [5].
In 2015, five randomized controlled trials demonstrated that endovascular thrombectomy was
effective in patients with proximal occlusions in carotid and circle of Willis circulatory system [6–10].
In addition to improving stroke outcome, this novel approach makes it possible to study in vivo
thrombotic material. Intra-arterial therapy, when performed with newer generation devices (mainly
stent retrievers), ensures that most of the thrombotic material is retrieved, as post-recanalization digital
substraction angiography shows [11]. Thus, this procedure represents an opportunity to study the
structure and composition of the occlusion-causing thrombi in stroke patients.
In this scenario, our study aimed to investigate the thrombotic material retrieved from AIS
patients by using a clinical proteomics approach. This thrombotic material is a valuable source to
identify candidate biomarkers for stroke diagnosis, as it mirrors the actual environment in which the
thrombus is organized, for example left atrial appendage in most cardioembolic strokes. Interestingly,
a comprehensive consensus statement has been recently published in order to provide a rational
approach for studying this valuable material [12]. Here, we performed a proteomic profiling in fresh
thrombus samples obtained from AIS patients who received intra-arterial therapy with thrombectomy.
2. Results
2.1. Proteme Exploration of Human Thrombus by Mass Spectrometry
We have used thrombi from four AIS patients (Table 1) with the aim of obtaining a deep insight
into the protein cargo and protein function of the thrombotic material isolated by endovascular
thrombectomy. To this purpose, we used an integrated experimental workflow combining peptide
fractionation coupled to mass spectrometry (Figure 1). The number of characterized proteins ranged
from 549 to 1264 proteins, identifying around 1600 different protein species in thrombotic material.
Complete lists of identifications are presented in Table S1.
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Table 1. Neuroimaging and clinical characteristics.
Clinical variables Case 1 Case 2 Case 3 Case 4
Age (years) 72 50 78 70
Gender male male male male
Stroke subtype CE 1 AT 2 AT 2 CE 1
Hypertension + − + +
Dyslipemia + − + −
Diabetes Mellitus − − + −
Atrial Fibrilation + − − +
Ipsilateral internal carotid status non stenosingplaques occlusion 50–69% stenosis non stenosing plaques
Smoke + + + +






ev Rtpa 3 +
Thrombectomy
ev Rtpa 3 +
Thrombectomy
Onset to recanalization time (min) 210 360 320 210
Arterial Segment Left MCA 4 Left ICA + MCA 4 Right MCA 4 Left MCA 4 + left ACA 5
Stent Retriever Dispositive pREset pREset pREset pREset
Number of passes 6 3 1 1 2(MCA 4) + 2(ACA 5)
TICI 7 scale 3 3 3 3
1 CE: cardioembolic stroke; 2 AT: atherotrombotic stroke; 3 Rtpa: recombinant Tissue Plasminogen Activator; 4 MCA:
medial cerebral artery; 5 ACA: anterior cerebral artery; 6 Number of passes: number of passes performed with the
stent retriever dispositive until recanalization; 7 TICI scale: Thrombolysis in Cerebral Infarction scale.
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2.2. Functional Mapping of Human Thrombotic Proteome Isolated by Endovascular Thrombectomy
To interpret the proteomic fingerprints from a functional point of view, global thrombotic
proteome dataset was functionally categorized. To this end, a signaling pathway characterization
from all thrombotic proteins was performed with the Ingenuity Pathway Analysis (IPA) software tool
(Qiagen, Redwood City, CA, USA). Some of the most significantly enriched pathways included
remodeling of epithelial adherens junctions, protein ubiquitination, mitochondrial dysfunction,
and acute phase response signaling, among others (Table 2 and Table S2). To deeply characterize the
biological pathways represented in the thrombotic protein cargo, subsequent analyses were performed
to extract the proteome distribution across molecular functions and biological processes. As shown in
Figure 2A, well-known biological process and molecular disturbances involved in the development
of ischemic stroke such as proliferation and cell death as well as activation and aggregation of
cells, and metabolism of ROS (Table S3) were significantly over-represented. Interestingly, part
of the identified proteome shows considerable immunological and cardiopathy-related functions,
blood cell–dependent functions, and perivascular processes (Figures 2B and 3 and Table S3). All these
functions are also closely implicated in ischemic stroke pathophysiology and its downstream
deleterious effects.
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Figure 3. Cardiopathy-related terms (A), blood-cell dependent functions (B), and peripheral vascular
processes (C) significantly represented according to the thrombotic proteome characterized in this
study (disease and functions from the global 1600 protein list).
Table 2. Significantly enriched pathways in our (global) thrombotic proteome dataset.
Canonical Pathways -Log (p-Value) % Thrombotic Proteins
Remodeling of Epithelial Adheren Junctions 2.51 × 10−1 56.1 37
Protein Ubiquitination Pathway 2.47 × 10−1 28.3 72
Mitoc o drial Dysfu ction 2.36 × 10−1 33.9 56
Acute Phase Response 2.23 × 10−1 32.7 55
Clathrin-mediated Endocytosis Signaling 2.18 × 10−1 30.1 59
Integrin Signaling 2.14 × 10−1 28.8 61
Caveolar-mediated Endocytosis Signaling 2.02 × 10−1 47.9 34
Phagosome Maturation 1.97 × 10−1 34.3 46
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Table 2. Cont.
Canonical Pathways -Log (p-Value) % Thrombotic Proteins
LXR/RXR Activation 1.83 × 10−1 34.7 42
Actin Cytoskeleton Signaling 1.82 × 10−1 26.1 58
Fcγ Receptor-mediated Phagocytosis in Macrophages and Monocytes 1.75 × 10−1 38.7 36
RhoGDI Signaling 1.49 × 10−1 26.7 46
Leukocyte Extravasation Signaling 1.44 × 10−1 24.4 50
Ephrin Receptor Signaling 1.42 × 10−1 26.2 45
Gap Junction Signaling 1.37 × 10−1 26.2 43
NRF2-mediated Oxidative Stress Response 1.32 × 10−1 24.2 46
2.3. Protein Interaction Networks for Common Proteins Present in the Thrombus
From our global dataset, 339 proteins have been identified in all patients, comprising a
“proteome reference map” (Figure 4 and Table S4). In addition, 78% of the common protein dataset
(265 out of 339 protein species) has been previously detected in plasma and/or serum according to
Plasma Proteome Database. Our data complements previous proteomic characterization of thrombus
or its constituent platelet cells (around 6700 proteins) using similar technological approaches [13–15].
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In total, around 160 protein species were identified.
Interestingly, four proteins have not been previously reported associated to platelets or thrombotic
material. In particular, protein-glutamine gamma-glutamyltransferase 2, Actin α cardiac muscle 1,
macrophage-capping protein, and putative elongation factor 1-α-like 3 has been unambiguously
identified in our sample set. Protein-glutamine gamma-glutamyltransferase 2 is an enzyme involved
in the conjugation of polyamines to proteins. Actin α cardiac muscle 1 participates in cell motility.
Macrophage-capping protein is a calcium-sensitive protein that reversibly blocks the pointed ends
of actin filaments. The canonical function of putative elongation factor 1-α-like 3 is to bind
aminoacyl-tRNA to the A-site of ribosomes in the process of protein biosynthesis. Most importantly,
no relationship between any of those proteins and stroke has been previously described.
To analyze the cooperative effects among the 341 thrombotic proteins, we constructed protein-scale
interaction networks. The network-based approach allowed us to: (i) identify the molecular context of
the highly connected nodes, (ii) map interactions between thrombotic proteins and functional modules,
(iii) detect potential causal modulators of thrombotic protein modules that may be considered as
proteins involved in thrombus formation (Figures 5 and 6). As shown in Figure 5, the main axis in the
network (A) corresponds to the functional relationship between fibronectin 1 and 14-3-3 family proteins.
Additionally, TGFβ signaling is also over-represented in the second network (B). Other functional
interactomes also suggest the involvement of TCP complex in the thrombus biology (Figure 6A).
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3. Discussion
Three years ago, a human proteome map was made available that comprised proteins and
polypeptides resulting from the activity of 17,294 genes [16]. Based on these discoveries, the rapid
development of proteomic techniques has boosted novel approaches to detect and identify specific
proteomes with potential impact in clinical research [17]. Thus, the use of proteomic procedures is on
the rise, as much for diagnosis as for gaining insight into pathological mechanisms. In the field of
stroke, there is also an increasing interest in benefiting from proteomics, on the one hand, to identify
biomarkers potentially useful for diagnosis, and on the other hand, to unveil new molecular pathways
involved in disease progression and thus identify new therapeutic targets.
In this scenario, and using a brain proteomics approach in stroke patients, Cuadrado et al.
compared protein expression in different areas of brain tissue (core, penumbra and non-ischemic areas)
identifying several proteins with differential expression that add knowledge of the ischemic cascade in
order to identify candidate biomarkers of diagnostic, therapeutic or prognostic value [18].
Furthermore, several circulating proteins have been identified as potentially useful
biomarkers [19–21]. Recently, Lind et al. developed a targeted proteomics chip including three
circulating proteins (NT-pro-BNP, adrenomedullin, and eosinophil cationic protein) that could
predict incident ischaemic stroke in two independent Swedish cohorts of adults aged over 70 years,
independently of established cardiovascular risk factors and prevalent atrial fibrillation. This study
confirms large-scale proteomics studies as a novel and exciting tool which is particularly significant in
the search for new biomarkers in cerebrovascular disease [22]. However, those proteomic approaches
have been performed on brain or peripheral blood samples, which may be affected by a number of
regional or systemic processes reducing the specificity of the discovered biomarkers.
To the best of our knowledge, thorough proteomic analyses of thrombi responsible for AIS
symptoms have not been reported so far. Studies usually focus on histological approaches to the
thrombus cellular component, as well as on applying immunohistochemical procedures to assess the
expression level of proteins previously known, or suspected, to be involved in thrombogenesis [23–29].
Unfortunately, those studies show contradictory findings, and some relevant information such as
associations between clot histology and stroke etiology are lack using Haemoatoxilin/Eosin (H&E)
staining [30]. However, immunostaining techniques can provide more precise information than H&E
staining regarding the origin of thrombus as they allow the study of distinct cells such as platelets,
T-cells or neutrophils [14]. As an example, a study revealed that atherothrombotic strokes showed
higher CD3þ T-cell counts in intracranial thrombi than all other causes of stroke [31]. Still, they show
limitations to fully uncover the molecular basis of ischemic stroke.
As shown in the Figure S1, high heterogeneity in cellular and fibrin content is clearly observed
inter- and intra-group in our samples. On the other hand, no vascular structures are shown into
the thrombus material, so we may infer that no mature thrombus has been included in our study.
As previously mentioned [12], heterogeneity of methods of quantitative analysis between different
studies and mainly heterogeneity of thrombus composition (composition may differ greatly in
a few millimeters between two contiguous sections of the thrombus) makes correlation between
thrombus components (RBCs, fibrin, platelets, white blood cells) and stroke etiology very difficult to
establish. However, our proteomic workflow has defined a common proteome subset of 339 proteins
independently of the thrombus origin, indicating that future quantitative proteomics approaches might
complement histology analysis at the time of characterizing the thrombi origin.
It must be remarked that Alonso-Orgaz et al. have recently reported the proteome profiling of
coronary thrombus [13]. By following an approach in line with ours, they were able to identify
a group of proteins, i.e., myosin-9, ras-related protein Rap-1b, fermitin homolog 3, β parvin,
and thrombospondin-1, whose functional features suggested that platelet focal adhesion mechanisms
were involved in thrombogenesis. Those findings afford us better knowledge of pathologic pathways
in thrombus formation in coronary arteries.
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In our study, we show, for the first time, a protocol to characterize the proteomic profiling of
thrombi in AIS patients. Some of the most significantly enriched pathways found in our work included
remodeling of epithelial adherens junctions, protein ubiquitination, mitochondrial dysfunction,
and acute phase response signaling, among others (Table 2 and Table S2). A number of these
pathways have been previously related to stroke such as protein ubiquinitation or mitochondrial
dysfunction. E3 ubiquitin ligases play an important role in post-translational modifications after
brain ischemic insult, being related to processes of neuronal survival and injury [32]. Moreover,
neuronal excitotoxicity is known to result in calcium overload and mitochondrial dysfunction in
stroke patients [33]. Finally, several molecules involved in acute phase response signaling pathway,
including IL-6 or TNF-α, have been consistently related to acute ischemic stroke [34–39] and stroke
recurrence [40].
Notably, activation and aggregation of cells, particularly platelets, is of utmost importance in
ischemic stroke, as thrombus formation is dependent on these biological processes. In addition,
stroke involves biological mechanisms that are ignited by activation of glutamate receptors that result
in high levels of intracellular Ca2+ and formation of reactive oxygen species (ROS) [41]. Interestingly,
part of the identified proteome shows relevant immunological and cardiopathy-related functions,
blood cell dependent functions, as well as perivascular processes (Figures 2B and 3). All these functions
are also involved in ischemic stroke pathophysiology and its downstream deleterious effects.
On the other hand, our interactome characterization showed several protein networks that may
be involved in the thrombus formation (Figures 5 and 6), such as the functional relationship between
fibronectin 1 and 14-3-3 family proteins. Additionally, TGFβ signaling is also over-represented
in the second network (B). Other functional interactomes also suggest the involvement of TCP
complex in the thrombus biology (Figure 6A). Notably, fibronectin was one of the first biomarkers
found to predict hemorrhagic transformation of ischemic stroke [42,43] and malignant cerebral
infarction [44]. Remarkably, 14-3-3 protein is involved in the platelet surface receptor, the glycoprotein
(GP) Ib-IX-V complex-dependent signaling, that initiates thrombus formation [45] and 14-3-3 isoforms
are known to be differentially induced to enter into the nuclei of neurons after ischemia-reperfussion
in rat models [46]. In addition, TGFβ signaling is a well-known character implicated in
neuroinflammation [47] and angiogenesis [48] after ischemic stroke.
Finally, it is also compelling that new data are revealed by using this clinical proteomics approach,
such as the connection of ischemic stroke with remodeling of epithelial adherens junctions pathway.
Although the involvement of endothelial cell junctions in stroke is well described [49], the role of
epithelial cell junctions is not clear and merits further research.
Study Limitations
We show results obtained from a limited cohort of patients, so our conclusions should be regarded
cautiously as far as the generalization of results is concerned. We included two patients with confirmed
cardioembolic stroke and two patients with carotid atherothrombotic occlusion and tandem medial
cerebral artery occlusion in order to cover the two most important causes of AIS.
We are aware that in situ propagation of the thrombus could modify the original thrombus or
what we call “head” of the thrombus. However, the short time between stroke onset and recanalization
would minimize in situ thrombus formation. Moreover, the thrombi were almost entirely extracted
with the stent-retrieved, as TICI grades were compatible with complete recanalization, so we assume
that this sample is representative of the actual composition of the thrombus. It might be also possible
that the retrieving procedure could minimally change its protein content, modifying the results in our
study, since manipulation with catheters might have induced some thrombi; however, thromboembolic
complications are reported in only 1% to 2% of cerebral angiographies [50].
On the other hand, we consider that drug therapies used before the mechanical thrombectomy,
i.e., pre-treatment with ASA, and especially with recombinant tissue plasminogen activator (rtPA),
could also modify the thrombus proteome. However, patients had been previously treated with rtPA
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(Table 1) as current guidelines recommendations [51], and this fact precluded us to investigate the
possible effect of thrombolytic agent in protein expression. Moreover, limited half-life of rtPA and the
short time between rtPA administration and thrombus extraction would prevent significant changes in
protein expression in our samples.
4. Materials and Methods
4.1. Ethics Considerations
A written consent form was obtained for research purposes from all patients included in this
study, according to the Spanish Law 14/2007 of Biomedical Research, and approved (31 August 2015)
by the Ethics Committee of the Complejo Hospitalario de Navarra.
4.2. Endovascular Thrombectomy
We selected four patients who had suffered an ischemic stroke and who had been treated with
endovascular procedures by following the guidelines available at present [52]. Stent-retrievers were
used to extract the thrombus. Endovascular procedures were performed through the femoral artery
under general anesthesia. After placing a femoral sheath, diagnostic cerebral angiography was
performed to visualize the occlusion site and the collateral channels. Afterwards, a guiding catheter
was placed in. Using selective angiography with a microcatheter, the occlusion clot was visualized.
The microcatheter then crossed the clot and was placed distally as previously described [53]. A Trevo™
stent was advanced and fully deployed distal to the clot. The stent was kept there for about 1–5 min
to fully expand into the clot. Finally, the device with the thrombus trapped was removed slowly,
maintaining a balloon inflated in distal internal carotid artery as well as continuous negative suction
in order to prevent distal migration of thrombotic material during retrieval.
The endovascular device was replaced as many times as necessary to remove the thrombus.
The modified thrombosis in cerebral infarction (TICI) scale was used to determine the extent of
recanalization [54]. Complete recanalization was defined as TICI grades 2b or 3.
4.3. Periprocedural Work-Up
Cardiovascular risk factors, clinical status, and National Institutes of Health Stroke Scale (NIHSS)
scores were recorded by stroke expert neurologists immediately before and after endovascular
procedures. Trial of Org 10172 in Acute Stroke Treatment (TOAST) classification system was used for
etiological classification.
4.4. Processing of Thrombus Material
Each thrombus was washed with cold saline solution in situ and stored at 4 ◦C until it was further
processed. Then, thrombi were washed with phosphate buffered saline (PBS) solution and weighed.
For their analysis, thrombi were divided in two pieces, one part showing greater thickness and more
compact texture, which we called the “head” of the thrombus, while the rest was named the “tail”
of the thrombus. We assumed that the head was the original thrombus, with potential information
about the origin, and the tail of the thrombus may mostly consist of fresh thrombus formed in situ,
which would therefore be less informative. Then, we divided the head of the thrombus into five similar
pieces, four of which were frozen at −80 ◦C until they were processed and the last one was fixed in
paraffin. The proteomic analysis was performed using the frozen samples.
4.5. Sample Preparation for Proteomic Analysis
Thrombotic material was homogenized in lysis buffer (7 M urea, 2 M thiourea, 4% (v/v) CHAPS,
50 mM DTT). The homogenates were spinned down at 100,000× g by ultracentifugation (1 h at 15 ◦C).
Bradford assay (Bio-rad) was used to estimate the protein concentration.
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4.6. Protein Analysis by LC-MS/MS
Protein extracts were precipitated with methanol/choloroform, and pellets dissolved in 6 M Urea,
Tris 100 mM pH 7.8. 10 ug of protein was enzymatic cleavage with trypsin as previously described [55]
and the resulting peptides were separated by by reverse phase chromatography using an Eksigent
nanoLC ultra 2D pump fitted with a 75 µm ID column (Eksigent 0.075 × 250). The sample load and
desalting, column gradient, and mass spectrometer setup have been described previously in detail [56].
4.7. Peptide Identification
MS/MS data were obtained using AnalystTF 1.5.2 (Sciex, Washington, WA, USA), and spectra
files were processed through Protein Pilot TM Software 5.0 (Sciex, Washington, WA, USA) using
ParagonTM Algorithm 5.0 [57] and searched against the concatenated target-decoy UniProt human
database. False discovery rate was performed as previously described [58], and mass spectrometry
raw data and the associated results have been deposited to the ProteomeXchange Consortium (http:
//proteomecentral.proteomexchange.org) via the PRIDE partner repository [59] with the dataset
identifiers PXD007666 (Reviewer account details: Username: reviewer70650@ebi.ac.uk; Password:
d5yK9ciY).
4.8. Bioinformatic Analysis
Proteomic data was analyzed by using Ingenuity® Pathway Analysis (IPA) tool (QIAGEN
Redwood City, CA, USA). This software helps to uncover highly represented functions and pathways
in omics datasets, along with revealing interactome networks. The IPA comparison analysis reports a
hierarchical ranking of signaling pathways based on the calculated p-value. The software generates
p-values by using Fisher’s exact test (p ≤ 0.05) on the comparison between each biological or
molecular event and the proteins based. To perform Venn diagrams, we have used the Venny tool
(http://bioinfogp.cnb.csic.es/tools/venny/index.html).
5. Conclusions
In the current report, we used a discovery platform combining endovascular thrombectomy,
qualitative proteomics, and physical/functional interaction data to determine the molecular
composition of thrombi of human origin in ischemic stroke. On the whole, our results proved
that proteomic studies in a target “tissue” of ischemic stroke are feasible and deliver important
data to enrich our understanding of stroke physiopathology. In particular, thrombi retrieved with
new endovascular devices in AIS patients provided us with an interesting material revealing robust
biological and molecular information, such as the reference proteomic fingerprint of human thrombus
described above.
One of the advantages of analyzing this thrombotic material may be the identification of specific
biomarkers related to the pathophysiology of thrombus formation, given that this material mirrors
the environment where the thrombus has been formed. In this context, our study opens the way
for the establishment of a quantitative approach necessary to detect and characterize potential novel
biomarkers in the stroke field. Hence, thrombus proteomics represents a promising perspective
to explore the mechanisms underlying ischemic stroke from the inside and to identify future
stroke biomarkers.
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